Tolerability of antiseizure medicines using Lithuanian version of the Liverpool Adverse Events Profile

Arminas Jasionis; Gabija Jasionytė; Rūta Mameniškienė

doi:10.1016/j.yebeh.2021.108371

Tolerability of antiseizure medicines using Lithuanian version of the Liverpool Adverse Events Profile

Epilepsy Behav. 2021 Oct 28:124:108371. doi: 10.1016/j.yebeh.2021.108371. Online ahead of print.

Authors

Arminas Jasionis¹, Gabija Jasionytė², Rūta Mameniškienė³

Affiliations

¹ Vilnius University, Center for Neurology, Vilnius, Lithuania.
² Vilnius University, Faculty of Medicine, Vilnius, Lithuania.
³ Vilnius University, Center for Neurology, Vilnius, Lithuania. Electronic address: ruta.mameniskiene@santa.lt.

PMID: 34757263
DOI: 10.1016/j.yebeh.2021.108371

Abstract

Objectives: To develop and validate a Lithuanian version of the Liverpool Adverse Events Profile (LT-LAEP), and to evaluate the main demographic, clinical, and pharmacological determinants of its score.

Materials and methods: We developed the LT-LAEP and examined its psychometric properties. People with epilepsy (PWE) were asked to fill in the LT-LAEP, the Generalized Anxiety Disorder scale-7 (GAD-7), the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), and a questionnaire addressing key demographic and clinical information. Antiseizure medicine (ASM) burden was expressed as a number of ASM and total drug load. Multiple linear regression analysis was used to determine the influence of various variables on LAEP results.

Results: The data of 157 participants with the established diagnosis of epilepsy and stable ASM regimen were included in the final analysis. The mean LT-LAEP score was 48.72 ± 13.65. High internal consistency (Cronbach's α = 0.912) and test-retest reliability (ICC = 0.801) were demonstrated. The most common adverse effects (AEs) were tiredness (24.8%) and memory problems (23.6%). Lithuanian version of the Liverpool Adverse Events Profile score significantly correlated with NDDI-E (r = 0.635, p < 0.001) and GAD-7 (r = 0.640, p < 0.001) scores. The correlation between LT-LAEP score and total drug load was weak (r = 0.243, p = 0.002). The significant predictors of higher LT-LAEP score were female sex (β = -4.768, p = 0.003), higher seizure frequency (β = 4.757, p < 0.001), and higher NDDI-E (β = 1.457, p < 0.001) and GAD-7 scores (β = 0.610, p = 0.007) (F(4,152) = 43.975, R² = 0.536, p < 0.001).

Conclusions: The LT-LAEP is a reliable and valid instrument for the evaluation of the AEs of ASM. A higher score of LT-LAEP is predicted by female sex, seizure frequency, and anxiety and depression levels rather than total drug load.

Keywords: Adverse effects; Adverse events profile; Antiseizure medicines; Anxiety; Depression; Epilepsy.